ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.79266
-0.75%
Brent Oil
83.95
0.47%
Bitcoin
62,981.09
2.93%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Canadá
  5. TSX
  6. Oncolytics Biotech Inc (ONC)

  7. Oncolytics Biotech Inc (ONC) Noticias

ONC

Oncolytics Biotech (ONC)

Oncolytics Biotech Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:TSX:ONC
FechaHoraFuenteTítuloSímboloCompañía
26/09/202307:00PR Newswire (US)THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTSTSX:ONCOncolytics Biotech Inc
01/06/202211:23PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - ONC.WTTSX:ONCOncolytics Biotech Inc
01/06/202211:21PR Newswire (Canada)IIROC Trading Halt - ONC.WTTSX:ONCOncolytics Biotech Inc
10/01/202210:57PR Newswire (US)New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024TSX:ONCOncolytics Biotech Inc
09/04/202110:56PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - ONCTSX:ONCOncolytics Biotech Inc
09/04/202110:56PR Newswire (Canada)IIROC Trade Resumption - ONCTSX:ONCOncolytics Biotech Inc
09/04/202110:53PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - ONCTSX:ONCOncolytics Biotech Inc
09/04/202110:52PR Newswire (Canada)IIROC Trading Halt - ONCTSX:ONCOncolytics Biotech Inc
27/12/201706:00PR Newswire (US)Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patien...TSX:ONCOncolytics Biotech Inc
05/12/201706:00PR Newswire (US)Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic B...TSX:ONCOncolytics Biotech Inc
04/12/201706:00PR Newswire (US)Oncolytics Biotech® to Present at the Oncolytic Virotherapy SummitTSX:ONCOncolytics Biotech Inc
30/11/201706:00PR Newswire (US)Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Canc...TSX:ONCOncolytics Biotech Inc
16/11/201716:00PR Newswire (Canada)Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®TSX:ONCOncolytics Biotech Inc
08/11/201706:00PR Newswire (US)Oncolytics Biotech® Inc. Announces 2017 Third Quarter ResultsTSX:ONCOncolytics Biotech Inc
02/11/201706:00PR Newswire (US)Oncolytics Biotech® Appoints Deborah Brown to Board of DirectorsTSX:ONCOncolytics Biotech Inc
11/10/201706:00PR Newswire (US)Oncolytics Biotech® to Present at the 2017 BIO Investor ForumTSX:ONCOncolytics Biotech Inc
19/09/201706:00PR Newswire (US)Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers ConferenceTSX:ONCOncolytics Biotech Inc
18/09/201706:00PR Newswire (US)Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast CancerTSX:ONCOncolytics Biotech Inc
14/09/201706:00PR Newswire (US)Oncolytics Biotech® Announces First Patient Treated in MUK eleven StudyTSX:ONCOncolytics Biotech Inc
11/09/201706:00PR Newswire (US)Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 CongressTSX:ONCOncolytics Biotech Inc
03/08/201706:00PR Newswire (US)Oncolytics Biotech® Inc. Announces 2017 Second Quarter ResultsTSX:ONCOncolytics Biotech Inc
01/08/201706:00PR Newswire (US)Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth ConferenceTSX:ONCOncolytics Biotech Inc
26/07/201706:00PR Newswire (US)Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 CongressTSX:ONCOncolytics Biotech Inc
29/06/201706:00PR Newswire (Canada)Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.TSX:ONCOncolytics Biotech Inc
27/06/201706:00PR Newswire (US)Oncolytics Biotech® Inc. Opens U.S. Based Office in San DiegoTSX:ONCOncolytics Biotech Inc
01/06/201708:44PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - ONC.WTTSX:ONCOncolytics Biotech Inc
01/06/201708:43PR Newswire (Canada)IIROC Trade Resumption - ONC.WTTSX:ONCOncolytics Biotech Inc
01/06/201708:27PR Newswire (US)Oncolytics Biotech® Announces Closing of Public Offering of UnitsTSX:ONCOncolytics Biotech Inc
24/05/201709:39PR Newswire (US)Oncolytics Biotech® Prices Public Offering of UnitsTSX:ONCOncolytics Biotech Inc
23/05/201718:09PR Newswire (US)Oncolytics Biotech® Announces Proposed Public OfferingTSX:ONCOncolytics Biotech Inc
 Showing the most relevant articles for your search:TSX:ONC

Su Consulta Reciente

COIN
ETHUSD
Ethereum
USI
USTECH100
US Tech 100
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
CCOM
SILVER
SILVER
NYSE
CVX
Chevron
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MCD
McDonalds
AMEX
XLV
Health Care Select Sector
AMEX
XLF
Financial Select Sector
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados